Submit Manuscript  

Article Details

Fish Hydrolysates: A Regulatory Perspective of Bioactive Peptides

[ Vol. 23 , Issue. 12 ]


Bert Gevaert, Lieselotte Veryser, Frederick Verbeke, Evelien Wynendaele and Bart De Spiegeleer   Pages 1052 - 1060 ( 9 )


For the first time introduced on the Japanese market, bioactive fish hydrolysates are now available all over the world as food supplements, functional food ingredients or nutricosmeceuticals. They are generally produced from low value fish waste, an almost inexhaustible source of raw material, and are sold as high value products, making them economically interesting from a manufacturer’s view point. Most of these products have health or structure/function claims on their packages with different actions like antihypertensive, blood-glucose lowering, anxiolytic, and skin anti-aging activities. Although the different regional legislations all aim to assure consumer safety and prevent misleading of the consumer, the number of legally approved fish hydrolysate containing products drastically differs among different regions. This is because products that have been positively evaluated based on safety and efficacy in one region were found to have not enough evidence for efficacy in another region. These findings call for further international harmonization of the regulation and classification of these products. Moreover, interaction studies of these bioactive products with the normal diet or medicines are generally not performed, keeping the consumer uninformed of the possible risks of combining these products with medicinal products or other food ingredients.


Bioactive marine peptides, fish hydrolysates, legal classification, regulatory affairs.


Drug Quality and Registration (DruQuaR) Group, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, B-9000 Ghent, Belgium.

Graphical Abstract:

Read Full-Text article